Carlo Incerti, MD

Carlo most recently held the position of Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs at Sanofi Genzyme.Prior to its acquisition by Sanofi in 2011, Carlo held a number of positions of increasing scope and responsibility at Genzyme Corporation, the company who pioneered the development of therapeutics for rare diseases , working first at the European Headquarters in the Netherlands (1993-2010) before being appointed Senior Vice President of Global Market Access (2010-2011) at the corporate headquarters in Boston, MA.

Before his time at Sanofi and Genzyme, Carlo was a founding shareholder, Board member and Chief Executive officer at Biofil S.r.l., a start-up active in the development, manufacturing and commercialization of systems for leukocyte depletion of blood and derivatives, which was acquired by Fresenius Kabi of Germany in 1993.

Prior to join industry Carlo was an Associate Professor of Endocrinology at the University of Modena, with a main research focus on thyroid diseases and sex hormones.

Dr. Incerti is also Chairman of the Board at Numab Therapeutics AG, a Swiss company active in the field of multi specific antibodies for immunology and cancer, Chairman of the Board at Azafaros B.V., a Dutch company developing small molecules for substrate inhibition in rare genetic diseases, a Member of the Board of Dyne Therapeutics Inc., a US clinical stage biopharmaceutical public company developing therapies for neuromuscular diseases, a Member of the Board of Synox Therapeutics Ltd., an Irish company developing therapies for a rare synovial tumor and a Founding Member of the of IRDiRC, the International Rare Diseases Research Consortium. Dr. Incerti was also Chairman of the Board of Inversago Pharma, which was sold to Novo Nordisk in 2023 and of Yellow Jersey Therapeutics, a spin off from Numab Therapeutics, which was sold in 2024 to Johnson & Johnson.